Addex Therapeutics (ADXN)
(Delayed Data from NSDQ)
$8.00 USD
-0.12 (-1.48%)
Updated Jul 24, 2024 09:58 AM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ADXN 8.00 -0.12(-1.48%)
Will ADXN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ADXN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADXN
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates
ADXN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q2 Loss, Misses Revenue Estimates
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
Other News for ADXN
After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate
Addex Therapeutics partner discontinues development of ADX71149
Addex?s Partner Discontinues ADX71149 development in Epilepsy
J&J ends work on Addex epilepsy drug candidate ADX71149: report
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)